Genetix Pharmaceuticals (Cambridge, MA) a clinical-stage gene therapy company whose lentiviral technology is focused upon severe genetic disorders such as adrenoleukodystrophy and beta-thalassemia, closed a $35M Series B financijng. Participants include Third Rock Ventures, Genzyme Ventures, TVM Capital, Forbion and Easton Capital.